Literature DB >> 7477431

Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study.

S Dhein1, M Schott, E Gottwald, W Klaus.   

Abstract

Quinidine and verapamil are widely used as antiarrhythmic agents and their combination is often used in the treatment of supraventricular tachycardia. This study was undertaken to clarify, whether these drugs exert proarrhythmic effects on the ventricles in therapeutic concentrations and whether possible arrhythmogenic effects might be enhanced by combination. Isolated rabbit hearts perfused according to the Langendorff technique were treated with increasing concentrations of quinidine (0.05 to 3.5 microM) or verapamil (5 to 50 nM) or of their combination (70:1 or 10:1, quinidine:verapamil) corresponding to common low, medium and high free therapeutic concentrations. The epicardial activation process was measured using a computer assisted mapping system for unipolar multichannel recording (256 channels simultaneously). Both substances prolonged the atrioventricular conduction time PQ. This effect was even more pronounced if the 70:1 combination was administered. The activation pattern was altered by both drugs and their combination to the same extent as became obvious from analysis of local activation vectors and of localisation of breakthroughpoints of epicardial activation for heart beats under control conditions and under drug treatment. The epicardial potential durations were prolonged by quinidine and to the same degree by the combinations, but not by verapamil alone. The total activation time was prolonged under the influence of quinidine and if the 70:1 combination was given. Both substances exerted a negative inotropic effect which was enhanced in an additive manner if both drugs were combined. In parallel the coronary flow was diminished.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477431     DOI: 10.1007/bf00169195

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  Spread of activation in the left ventricular wall of the dog. II. Activation conditions at the epicardial surface.

Authors:  D DURRER; L H VAN DER TWEEL
Journal:  Am Heart J       Date:  1954-02       Impact factor: 4.749

2.  Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization.

Authors:  M A Habbab; N el-Sherif
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

3.  Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry.

Authors:  M S Spach; P C Dolber; J F Heidlage
Journal:  Circ Res       Date:  1989-12       Impact factor: 17.367

4.  Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.

Authors:  P L Rensma; M A Allessie; W J Lammers; F I Bonke; M J Schalij
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

5.  Inhibition of ATP-sensitive potassium channels of adult rat heart cells by antiarrhythmic drugs.

Authors:  R A Haworth; A B Goknur; H A Berkoff
Journal:  Circ Res       Date:  1989-10       Impact factor: 17.367

6.  Accelerated repolarization as a factor in re-entry--stimulation of the electrophysiology of acute myocardial infarction.

Authors:  J Geddes; M J Burgess; K Millar; J A Abildskov
Journal:  Am Heart J       Date:  1974-07       Impact factor: 4.749

7.  A new method for analysing the geometry and timecourse of epicardial potential spreading.

Authors:  S Dhein; P Rutten; W Klaus
Journal:  Int J Biomed Comput       Date:  1988-12

8.  The effects of antiarrhythmic drugs, stimulation frequency, and potassium-induced resting membrane potential changes on conduction velocity and dV/dtmax in guinea pig myocardium.

Authors:  J W Buchanan; T Saito; L S Gettes
Journal:  Circ Res       Date:  1985-05       Impact factor: 17.367

9.  Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations.

Authors:  C S Kuo; K Munakata; C P Reddy; B Surawicz
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

10.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  1 in total

1.  Effect of calcium-channel antagonist on repolarization heterogeneity of ventricular myocardium in an in vitro rabbit model of long QT syndrome.

Authors:  Guoan Zhao; Jun Pu; Cuntai Zhang; Yexin Ma; Bo Li; Xiaoqing Quan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.